← boardnext 2027-01next 2027-03next 2027-12
PCVX
Vaxcyte, Inc.distress 2/10 · well-funded / low risk$55.52-1%today-12% from 52w high
Infectious Disease 1
Lead: Pneumococcal Vaccines
Revenue
pre-revenue
Liquidity
$2741M
Runway
3.6 yrs
Shares 1y
+11%
Price & events
+3.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
-0.8%
1D
-0.9%
1W
+6.9%
1M
-8.6%
3M
+5.3%
6M
+52.3%
1Y
-33.9%
2Y
+146.6%
5Y
+105.6%
All
Overview
- Market Cap
- $8.02B
- Volume
- 33.26K
- 52 Week Range
- $29.67 – $63.04
- Total Shares
- 144.40M
- Float Shares
- 132.21M
- Short %
- 12.16%
- % Held by Insiders
- 0.50%
- % Held by Institutions
- 113.90%
- RVOL
- 0.02x
- Beta
- 1.22
Pipeline stages · 4 programs
31-valent pneumococcal conjugate vaccine, PCV20
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX-
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 5 trials · 4 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-01 Estimated 50% readout ~2027-03-17 | Phase 3 | 31 valent pneumococcal conjugate vaccine, PCV20, PCV21 | Pneumococcal Vaccines | — | active not recruiting |
| 2027-03 Estimated 50% readout ~2027-05-15 | Phase 3 | 31-valent pneumococcal conjugate vaccine, PCV20 | Pneumococcal Vaccines | — | active not recruiting |
| 2027-03 Estimated 50% readout ~2027-05-15 | Phase 3 | 31-valent pneumococcal conjugate vaccine, Seasonal Influenza Vaccine (SIV) (Flublok) | Pneumococcal Vaccines | — | active not recruiting |
| 2027-12 Estimated 50% readout ~2028-01-15 | Phase 2 | 0.5 mL of the low dose VAX-31, 0.5 mL of the mid dose VAX-31, 0.5 mL of the high dose VAX- | Pneumococcal Vaccines | — | active not recruiting |
| 2025-08-25 | Phase 2 | 0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24 | Pneumococcal Vaccines | 802 | completed |
Catalyst news & presentations · 7
- 2026Guided 40%readoutPhase 3VAX-31 · Topline safety, tolerability, immunogenicity dataSEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- mid-2026readoutPhase 2VAX-31 · Topline Phase 2 dose-finding data for primary three-dose immunization seriesSEC 8-K
- by end of 2025readoutPhase 2VAX-24 · Topline data from booster doseSEC 8-K
- mid-2025trial initiationsecondaryPhase 3VAX-31 · Initiate Phase 3 non-inferiority studySEC 8-K
- first quarter of 2025trial initiationsecondaryPhase 2VAX-31 · Initiate Phase 2 infant study following IND clearanceSEC 8-K
- by end of first quarter of 2025readoutPhase 2VAX-24 · Topline safety, tolerability and immunogenicity data from primary three-dose immunization seriesSEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $109 (+96% upside) · 9 analysts
- 2026-02-26BTIGBuy
- 2026-02-02GuggenheimBuy
- 2025-11-10BTIGBuy
- 2025-10-16BTIGBuy
- 2025-09-12Goldman SachsNeutral
- 2025-04-22Cantor FitzgeraldOverweight
Competitors — Pneumococcal Vaccines
- none identified
Recent news
- 2026-07-22Vaxcyte: Clinical-Stage Vaccine Disrupter With Vast Near-Term Potential - Seeking Alpha
- 2026-07-21RTA Outdoor Living Tops 1,000 Google Reviews With a 5-Star Rating for Outdoor Kitchens Sold Entirely Online - GlobeNewswire
- 2026-07-21Vaxcyte stock consolidates after raising fresh capital and advancing PCVX vaccine pipeline - Ad-hoc-news.de
- 2026-07-20Why (PCVX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
- 2026-07-16Form 4 Vaxcyte Inc For: 16 July By Investing.com - Investing.com Nigeria
- 2026-07-16Vaxcyte, Inc. (PCVX) awards 23,029 stock options to director John Markels - Stock Titan
- 2026-07-16Vaxcyte, Inc. (PCVX) director files Form 3 reporting zero holdings - Stock Titan
- 2026-07-16Is Vaxcyte's VAX-31 a Game-Changer in the Vaccine Landscape - Kavout | AI
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.